Selected research
Market Structure
Global Romosozumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Romosozumab market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Romosozumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Romosozumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Romosozumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Romosozumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Romosozumab include Thermo Fisher Scientific, Bristol-Myers Squibb and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Romosozumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Romosozumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Romosozumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Romosozumab market size, projected growth trends, production technologies, key applications, and end-use industries.
Romosozumab Segment by Company
Thermo Fisher Scientific
Bristol-Myers Squibb
Celgene
Romosozumab Segment by Type
25 mg/vial
75 mg/vial
Romosozumab Segment by Application
Beta-thalassemia
MDS-RS
Romosozumab Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Romosozumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Romosozumab and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Romosozumab.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Romosozumab market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Romosozumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Romosozumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Romosozumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 25 mg/vial
- 75 mg/vial
Applications
- Beta-thalassemia
- MDS-RS
Companies covered
- Thermo Fisher Scientific
- Bristol-Myers Squibb
- Celgene
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Romosozumab Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Romosozumab Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Romosozumab Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Romosozumab Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Romosozumab Market Dynamics
- 2.1 Romosozumab Industry Trends
- 2.2 Romosozumab Industry Drivers
- 2.3 Romosozumab Industry Opportunities and Challenges
- 2.4 Romosozumab Industry Restraints
3 Romosozumab Market by Manufacturers
- 3.1 Global Romosozumab Revenue by Manufacturers (2021-2026)
- 3.2 Global Romosozumab Sales by Manufacturers (2021-2026)
- 3.3 Global Romosozumab Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Romosozumab Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Romosozumab Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Romosozumab Manufacturers, Product Type & Application
- 3.7 Global Romosozumab Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Romosozumab Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Romosozumab Players Market Share by Revenue in 2025
- 3.8.3 2025 Romosozumab Tier 1, Tier 2, and Tier 3
4 Romosozumab Market by Type
- 4.1 Romosozumab Type Introduction
- 4.1.1 25 mg/vial
- 4.1.2 75 mg/vial
- 4.2 Global Romosozumab Sales by Type
- 4.2.1 Global Romosozumab Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Romosozumab Sales by Type (2021-2032)
- 4.2.3 Global Romosozumab Sales Market Share by Type (2021-2032)
- 4.3 Global Romosozumab Revenue by Type
- 4.3.1 Global Romosozumab Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Romosozumab Revenue by Type (2021-2032)
- 4.3.3 Global Romosozumab Revenue Market Share by Type (2021-2032)
5 Romosozumab Market by Application
- 5.1 Romosozumab Application Introduction
- 5.1.1 Beta-thalassemia
- 5.1.2 MDS-RS
- 5.2 Global Romosozumab Sales by Application
- 5.2.1 Global Romosozumab Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Romosozumab Sales by Application (2021-2032)
- 5.2.3 Global Romosozumab Sales Market Share by Application (2021-2032)
- 5.3 Global Romosozumab Revenue by Application
- 5.3.1 Global Romosozumab Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Romosozumab Revenue by Application (2021-2032)
- 5.3.3 Global Romosozumab Revenue Market Share by Application (2021-2032)
6 Global Romosozumab Sales by Region
- 6.1 Global Romosozumab Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Romosozumab Sales by Region (2021-2032)
- 6.2.1 Global Romosozumab Sales by Region (2021-2026)
- 6.2.2 Global Romosozumab Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Romosozumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Romosozumab Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Romosozumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Romosozumab Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Romosozumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Romosozumab Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Romosozumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Romosozumab Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Romosozumab Revenue by Region
- 7.1 Global Romosozumab Revenue by Region
- 7.1.1 Global Romosozumab Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Romosozumab Revenue by Region (2021-2026)
- 7.1.3 Global Romosozumab Revenue by Region (2027-2032)
- 7.1.4 Global Romosozumab Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Romosozumab Revenue (2021-2032)
- 7.2.2 North America Romosozumab Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Romosozumab Revenue (2021-2032)
- 7.3.2 Europe Romosozumab Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Romosozumab Revenue (2021-2032)
- 7.4.2 Asia-Pacific Romosozumab Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Romosozumab Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Romosozumab Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Thermo Fisher Scientific
- 8.1.1 Thermo Fisher Scientific Company Information
- 8.1.2 Thermo Fisher Scientific Business Overview
- 8.1.3 Thermo Fisher Scientific Romosozumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Thermo Fisher Scientific Romosozumab Product Portfolio
- 8.1.5 Thermo Fisher Scientific Recent Developments
- 8.2 Bristol-Myers Squibb
- 8.2.1 Bristol-Myers Squibb Company Information
- 8.2.2 Bristol-Myers Squibb Business Overview
- 8.2.3 Bristol-Myers Squibb Romosozumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Bristol-Myers Squibb Romosozumab Product Portfolio
- 8.2.5 Bristol-Myers Squibb Recent Developments
- 8.3 Celgene
- 8.3.1 Celgene Company Information
- 8.3.2 Celgene Business Overview
- 8.3.3 Celgene Romosozumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Celgene Romosozumab Product Portfolio
- 8.3.5 Celgene Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Romosozumab Value Chain Analysis
- 9.1.1 Romosozumab Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Romosozumab Production Mode & Process
- 9.2 Romosozumab Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Romosozumab Distributors
- 9.2.3 Romosozumab Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst